Evidence map›Paper›PMID 15365734›Full record

Trial reportZeitschrift fur Kardiologie2004

Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial.

U Burkhardt, R Zahn, U Höffler, K E Siegler, B Frilling, M Weber, M Gottwik, M Wehr, F Seidel, S Rosocha and 2 more

Abstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Zeitschrift fur Kardiologie, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.Clinical research in cardiology : official journal of the German Cardiac Society · 2014
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

U BurkhardtInstitut für Mikrobiologie und Hygiene, Städt. Klinikum, Bremserstr. 79, 67063 Ludwigshafen, Germany.
R Zahn
U Höffler
K E Siegler
B Frilling
M Weber
M Gottwik
M Wehr
F Seidel
S Rosocha
U Tebbe
J Senges
Klinikum Ludwigshafen · DEAugusta-Kranken-Anstalt · DEHelios Amper-Klinikum Dachau · DEInstitute of Medical Microbiology and Hygiene · DEKempten University of Applied Sciences · DEKlinikum Lippe · DENuremberg Hospital · DEStädtisches Klinikum Dessau · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResults of studies concerning prevention of cardiovascular disease by treatment with macrolide antibiotics targeting C. pneumoniae infection are still controversial. This study describes the results of different tests for infection with C. pneumoniae as well as the effect of treatment with roxithromycin in patients with acute myocardial infarction (AMI) in relation to their serostatus against C. pneumoniae.

methodsWe analysed blood of 160 patients who came from the ANTIBIOtic therapy after an AMI ( ANTIBIO-) study, a prospective, randomised, placebo-controlled, double-blind study to investigate the effect of roxithromycin 300 mg/OD for 6 weeks in patients with an AMI. Anti- Chlamydia IgG-, IgA-, and IgM-antibodies of these patients were analysed by means of different test systems.

resultsThere was a good correlation between the two IgG and IgA methods (r = 0.900, p < 0.001 and r = 0.878, p < 0.001, respectively), but marked differences in the prevalence of positive tests. This resulted in only moderate concordance values, as expressed by the Kappa coefficients, for IgG kappa = 0.611 (95% CI = 0.498-0.724, p < 0.001) and for IgA kappa = 0.431 (95% CI: 0.322-0.540, p < 0.001). No significant association between positive C. pneumonia titers and the combined clinical endpoint during the 12 month follow-up could be found. In all test systems used, patients with positive anti- C. pneumoniae titers did not benefit from roxithromycin therapy (p = ns).

conclusionDepending on the test system used, there are large differences in the prevalence of anti- C. pneumoniae seropositive patients. Clinical events during the 12 month follow-up after AMI did not depend on serostatus against C. pneumoniae and treatment with roxithromycin did not influence these events, independently of the serostatus against C. pneumoniae. However, the power of this subgroup analysis was low to detect small but significant differences.

Indexed as

Chlamydophila InfectionsAnti-Bacterial AgentsAntibodies, BacterialChi-Square DistributionChlamydophila pneumoniaeComplement Fixation TestsData Interpretation, StatisticalDouble-Blind MethodElectrocardiographyFollow-Up StudiesHumansImmunoenzyme TechniquesImmunoglobulin AImmunoglobulin GImmunoglobulin MMyocardial InfarctionAnti-Bacterial AgentsAntibodies, BacterialImmunoglobulin AImmunoglobulin GImmunoglobulin MPlacebosRoxithromycin

Identifiers

PMID15365734
OpenAlexW15308580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.